PuraMed BioScience® Expands International Distribution with Order from Colombia, South America
SCHOFIELD, Wis., May 13, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (PMBS: OTCBB), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announces the receipt of its first International order for LipiGesic® M its non-drowsy, clinically tested, over-the-counter migraine relief product.
Through an agreement with Biokemical, PuraMed BioScience has now expanded international distribution of LipiGesic M to Columbia, South America.
"We are pleased that we have reached an agreement with Biokemical for distribution of LipiGesic M in Colombia, South America," said Russ Mitchell, CEO of PuraMed BioScience. "We anticipate a warm reception of our product given the country's view of the health value of homeopathic formulations. We anticipate this is a stepping-stone to our international expansion to Latin America."
Biokemical initiated the agreement after researching LipiGesic M. A spokesperson for Biokemical said the company is very interested in distributing the product initially in Colombia, with additional plans of expansion to other markets such as Peru, Ecuador, and Central America.
Biokemical has extensive experience in the distribution and marketing of pharmaceuticals and consumer products with wholesalers and pharmacy chains representing 70% of the pharmaceutical market in Columbia. The company has products placed in more than 2000 pharmacies as well as the 3rd largest supermarket chain in the country. Biokemical has experience working with multinational corporations such as Nestle, Reckitt Benckiser, Johnson & Johnson, and GlaxoSmithKline and has plans to create a distribution network for several product categories including migraine treatment products.
About LipiGesic® M
LipiGesic M is a patented, sublingual, homeopathic formulation of feverfew and ginger that has been clinically tested by leading headache experts with results published in leading medical journals finding it a highly effective treatment of acute migraine pain. LipiGesic M does not contain aspirin, acetaminophen, or caffeine; does not cause drowsiness; and has an excellent safety profile. For more information visit www.lipigesic.com/about.
About PuraMed BioScience, Inc.
PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to LipiGesic M, PuraMed BioScience plans to launch LipiGesic® H for tension-type headaches and LipiGesic® PM, which provides a remedy for insomnia and other sleep disorders. For more information visit http://www.puramedbioscience.com/about-us/.
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties that may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
South Street Media, Inc
Phone: (917) 937-8968
SOURCE PuraMed BioScience, Inc.